# Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

> **NCT06647888** · — · RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 12000 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Envlo Tablet
- **DRUG:** Envlomet SR Tablet

## Key facts

- **NCT ID:** NCT06647888
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 12000 (ESTIMATED)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647888, "Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06647888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*